Insider Selling: Revolution Medicines (NASDAQ:RVMD) COO Sells 4,583 Shares of Stock

Key Points

• Insider sale: COO Margaret Horn sold 4,583 shares on March 17 at an average price of $99.48 for a total of $455,916.84, reducing her ownership by 2.83% to 157,570 shares, according to the SEC filing.
• Company performance & analyst view: Shares trade near $99.29 with a $19.68B market cap and the company reported quarterly EPS of -$1.86 (missing estimates); analysts hold a consensus Buy rating with a $78.94 price target.

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) COO Margaret Horn sold 4,583 shares of the business's stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $455,916.84. Following the completion of the sale, the chief operating officer owned 157,570 shares in the company, valued at $15,675,063.60. This represents a 2.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Revolution Medicines Price Performance

Shares of NASDAQ RVMD traded up $1.18 on Thursday, hitting $99.29. The company's stock had a trading volume of 1,485,201 shares, compared to its average volume of 2,335,170. Revolution Medicines, Inc. has a 12-month low of $29.17 and a 12-month high of $124.49. The company has a market capitalization of $19.68 billion, a price-to-earnings ratio of -16.80 and a beta of 0.99. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.14 and a quick ratio of 7.14. The stock has a 50 day moving average of $103.58 and a 200-day moving average of $76.24.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same period in the previous year, the business posted ($1.12) earnings per share. As a group, research analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of RVMD. PNC Financial Services Group Inc. increased its position in shares of Revolution Medicines by 1.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company's stock worth $802,000 after acquiring an additional 125 shares in the last quarter. Deutsche Bank AG raised its stake in shares of Revolution Medicines by 0.4% in the 4th quarter. Deutsche Bank AG now owns 32,217 shares of the company's stock valued at $2,566,000 after acquiring an additional 130 shares during the period. Signaturefd LLC lifted its holdings in shares of Revolution Medicines by 33.1% during the 4th quarter. Signaturefd LLC now owns 656 shares of the company's stock valued at $52,000 after acquiring an additional 163 shares in the last quarter. Allworth Financial LP boosted its position in Revolution Medicines by 57.2% during the 4th quarter. Allworth Financial LP now owns 577 shares of the company's stock worth $46,000 after purchasing an additional 210 shares during the period. Finally, Farther Finance Advisors LLC boosted its position in Revolution Medicines by 44.7% during the 4th quarter. Farther Finance Advisors LLC now owns 751 shares of the company's stock worth $60,000 after purchasing an additional 232 shares during the period. Hedge funds and other institutional investors own 94.34% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Evercore upgraded Revolution Medicines to a "strong-buy" rating in a research report on Wednesday, February 25th. UBS Group started coverage on shares of Revolution Medicines in a report on Friday, February 27th. They set a "buy" rating for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Revolution Medicines in a research report on Thursday, January 22nd. Benchmark restated an "overweight" rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. Finally, Jefferies Financial Group started coverage on shares of Revolution Medicines in a research note on Monday. They issued a "buy" rating for the company. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $78.94.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.